Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,803 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,155 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03263650 | Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC | completed | Phase 2 | 96 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04751929 | Abemaciclib With or Without Atezolizumab for mCRPC | completed | Phase 2 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07648745 |
| Does Cediranib Prevent Bowel Perforation in Platinum-resistant Ovarian Cancer(CEBOC) |
| completed |
| Phase 2 |
| 30 |
| Prof Gordon JaysonOTHER |
| 1 |
| Jun 15, 2026 |
| clinicaltrials |
| NCT02759588 | Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer | completed | Phase 1 / Phase 2 | 46 | Genelux CorporationINDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03652493 | Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway(PRO-CARBO) | completed | Phase 2 | 16 | Centre Francois BaclesseOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04463771 | Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.(POD1UM-204) | completed | Phase 2 | 206 | Incyte CorporationINDUSTRY | 7 | Jun 11, 2026 | clinicaltrials |
| NCT05730712 | Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 7 | Mayo ClinicOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT05964361 | First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients(IL15-TransDC) | completed | Phase 1 / Phase 2 | 10 | University Hospital, AntwerpOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT01171898 | Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC) | completed | Phase 1 / Phase 2 | 127 | Aragon Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06434909 | CYTALUX™for the Intraoperative Imaging of Prostate Cancer | completed | Phase 2 | 9 | Indiana UniversityOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT02755844 | Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients(ENDOLA) | completed | Phase 1 / Phase 2 | 35 | Hospices Civils de LyonOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT03570827 | Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy | completed | Phase 2 | 53 | Mayo ClinicOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT03934840 | CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone | completed | Phase 2 | 61 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT03430700 | Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer(PROMPT) | completed | Phase 2 | 20 | University College, LondonOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT03910660 | A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype. | completed | Phase 1 / Phase 2 | 98 | BioXcel Therapeutics IncINDUSTRY | 2 | May 15, 2026 | clinicaltrials |
| NCT04019964 | Nivolumab in Biochemically Recurrent dMMR Prostate Cancer | completed | Phase 2 | 8 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT03604757 | 68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Prostate Cancer Imaging According to Various Metastatic Risks(UROPET) | completed | Phase 2 | 22 | University Hospital, BordeauxOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04731844 | Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer | completed | Phase 2 | 30 | University of RochesterOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT00959647 | A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study | completed | Phase 2 | 19 | Genentech, Inc.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT05114746 | Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan | completed | Phase 2 | 94 | Novartis PharmaceuticalsINDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT07568444 | Enhancing Readability of Lay Abstracts and Summaries for Medical Knowledge Using Generative Artificial Intelligence (BRIDGE AI 3) | completed | Phase 2 | 120 | University of Southern CaliforniaOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05005728 | XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 72 | Xencor, Inc.INDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT03797326 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | completed | Phase 2 | 611 | Merck Sharp & Dohme LLCINDUSTRY | 17 | May 4, 2026 | clinicaltrials |
| NCT02649855 | Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer | completed | Phase 2 | 74 | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2026 | clinicaltrials |
| NCT05133440 | A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones | completed | Phase 2 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05156268 | A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma | completed | Phase 2 | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT04925648 | Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction(PICASSO) | completed | Phase 2 | 4 | St Vincent's Hospital, SydneyOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT01902680 | Phase II Study of Feasibility of Focal Therapy for Prostate Cancer of Good Prognosis With Permanent I125 Localized Implant.(CURIEFOCALE) | completed | Phase 2 | 18 | Institut Claudius RegaudOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT02225704 | Radium-223 in Combination With Enzalutamide | completed | Phase 2 | 45 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT02772588 | AASUR in High Risk Prostate Cancer | completed | Phase 2 | 64 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03694262 | The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)(EndoBARR) | completed | Phase 2 | 30 | Medical College of WisconsinOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03612791 | Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab(ATEZOLACC) | completed | Phase 2 | 189 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT03496805 | Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy | completed | Phase 2 | 106 | Wake Forest University Health SciencesOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT02122185 | Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 111 | University of ChicagoOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT03617679 | Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer | completed | Phase 2 | 79 | University of Colorado, DenverOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT06036836 | Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) | completed | Phase 2 | 163 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Mar 19, 2026 | clinicaltrials |
| NCT04814108 | A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma | completed | Phase 2 | 92 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY | 4 | Mar 18, 2026 | clinicaltrials |
| NCT05198804 | A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 117 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY | 2 | Mar 18, 2026 | clinicaltrials |
| NCT01303094 | Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue Sarcoma(T-DIS) | completed | Phase 2 | 53 | Centre Oscar LambretOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT04300647 | A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer(SKYSCRAPER-04) | completed | Phase 2 | 172 | Hoffmann-La RocheINDUSTRY | 17 | Mar 12, 2026 | clinicaltrials |
| NCT02213913 | Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas | completed | Phase 1 / Phase 2 | 55 | University of ChicagoOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT02867956 | Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer | completed | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04341883 | Study of Anti-PD-1 Combined With Albumin-Bound Paclitaxel in Patients With Recurrent Cervical Cancer | completed | Phase 2 | 27 | Sun Yat-sen UniversityOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05494580 | Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 29 | Sun Yat-sen UniversityOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04332653 | NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 215 | NeoImmuneTechINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05008900 | Timing of Post-prostatectomy PSMA Imaging(TOPP) | completed | Phase 2 | 4 | University Health Network, TorontoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04288687 | A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects | completed | Phase 2 | 11 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT01409200 | Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis | completed | Phase 2 | 73 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT04443062 | Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer(Bullseye) | completed | Phase 2 | 58 | Radboud University Medical CenterOTHER | 2 | Feb 27, 2026 | clinicaltrials |
| NCT06056791 | Study of INKmune in Patients With mCRPC (CaRe Prostate)(CaRe) | completed | Phase 1 / Phase 2 | 12 | Inmune Bio, Inc.INDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jun 17, 2026source: clinicaltrials